Paul Atkins · SEC speeches and statements
“One biotech company in particular reported spending around $11 million on that compliance obligation alone since it crossed the $700 million public float threshold in 2021, roughly the cost of running a large Phase 2 clinical trial.”
Verbatim excerpt with a timestamp. The full recording is at the source; we link out and do not host it. Everything Paul Atkins is on record saying.